As Shares Fall Amid Fiscal Fourth-Quarter Struggles, Canopy Pushes Back EBITDA Profitability to 2024

Business Strategy & Outlook

Canopy Growth grows and sells cannabis products primarily in Canada, which accounts for roughly 50% of sales. Non-THC product sales account for about 30%. Canadian recreational accounts for roughly 60% of cannabis sales. Although the medical market to shrink as consumers turn to the recreational market, and more than 10% average annual growth for the entire Canadian market through 2030, driven by the conversion of black-market consumers into the legal market and new cannabis consumers.

Canopy also exports medical cannabis globally. The global market looks lucrative, given higher prices and growing acceptance of cannabis’ medical benefits. Exporters must pass strict regulations to enter markets, protecting early entrants like Canopy. Partially offsetting the global markets’ potential for Canadian producers are threats of future production from countries with cheaper labor— the single largest cost. However, many Canadian companies have pulled back expansion plans given ongoing cash burn. As per forecast around 15% average annual growth through 2030.

Canopy has a standing deal to acquire Acreage Holdings, a U.S. multistate operator, immediately upon federal legalization. The Canopy paid a good price and acquired an attractive option for an accelerated entry into the U.S. Canopy also owns 27% of U.S. multistate operator Terraced on a fully diluted basis. These U.S. assets look far more attractive than the continued challenges in the Canadian market. The U.S. market is murky, with some states legalizing recreational or medical cannabis while it remains illegal federally. The federal law will be changed to recognize states’ choices on legality within their borders, which would trigger Canopy’s deals. Based on state-by-state analysis, the nearly 20% average annual growth for the U.S. recreational market and nearly 10% for the medical market through 2030. Constellation Brands owns 38.6% of Canopy with additional securities that could push ownership to 55.8%. The investment as supportive of developing branded cannabis consumer products while also providing a funding backstop and foothold into the U.S. non-THC market.

Financial Strengths

On one hand, Canopy Growth’s debt remains relatively low. At the end of the fourth quarter of fiscal 2022, the company had about CAD 1.5 billion of debt compared with a market capitalization of roughly CAD 2.5 billion. On the other hand, the company continues to burn cash, which pressures its financial health. However, management has been focused on reducing capital spending and rightsizing its overhead, minimizing the need for further outside capital. The company will generate positive adjusted EBITDA in fiscal 2025 and positive free cash flow in fiscal 2026. The company’s target of positive adjusted EBITDA in fiscal 2024 looks possible in the latter half of the year, but no one had anticipate losses for the sum of the year. In the latter 10-year forecast, we think the company will generate enough positive free cash flow to reduce its debt. Benefiting its financial health, Canopy has generally relied on equity to fund acquisitions and expansion. The company’s first major debt raise occurred as recently as its first quarter of fiscal 2019. The company will continue to rely on equity to fund capital needs, which is typical for growth companies such as Canopy to help alleviate potential pressure on its financial health. Constellation Brands as a major strategic investor also adds a stabilizing presence to Canopy’s financial health.

Bulls Say

Canopy Growth’s deal to acquire Acreage Holdings immediately upon U.S. federal legalization provides exposure to the largest potential cannabis market in the world.

Canopy Growth’s ownership of 27% of Terrascend gives it further optionality for the U.S. THC market.

The investment by Constellation Brands and partnerships with Martha Stewart and Snoop Dogg provide potential expansion opportunities into infused products and topicals. If successful, Constellation Brands may increase its ownership or try to acquire Canopy.

Company Description

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and Craft Grow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

(Source: Morningstar)

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Laverne and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Laverne and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Laverne and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Laverne and Banyan Tree do and seek to do business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Laverne and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Laverne and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Laverne and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Laverne and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and are not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Laverne and Banyan Tree.